Anti-Fibrotic Drug Rentosertib Reduces Proteomic Clock Age in Humans
Rentosertib is a TNIK inhibitor developed by In Silico Medicine in the course of the company's efforts to find drugs that can affect aging, shown to be anti-fibrotic, and thus recently in a phase 2 trial for the treatment of idiopathic pulmonary fibrosis. Here, the researchers provide evidence from
<p>Rentosertib is a TNIK inhibitor developed by In Silico Medicine in the course of the company's efforts to find drugs that can affect aging, shown to be anti-fibrotic, and thus recently in a phase 2 trial for the treatment of idiopathic pulmonary fibrosis. Here, the researchers provide evidence from </p>